Abstract
Serotonin reuptake inhibitors may increase symptoms of anxiety immediately following treatment initiation. The present study examined whether acute citalopram increased fear-potentiated startle to predictable and/or unpredictable shocks in healthy subjects. Eighteen healthy subjects each received two treatments, placebo and 20 mg citalopram in a crossover design. Participants were exposed to three conditions including one in which predictable aversive shocks were signaled by a cue, a second in which unpredictable shocks were anticipated, and a third in which no shocks were administered. Changes in aversive states were investigated using acoustic startle stimuli. Citalopram did not affect baseline startle. However, the phasic startle potentiation to the threat cue in the predictable condition was robustly increased by acute citalopram. The sustained startle potentiation in the unpredictable conditions was also increased by citalopram, but only when the drug was given during the first session. These results indicate that a single dose of citalopram is not anxiogenic in itself, but can exacerbate the expression of fear and anxiety.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ (2001). Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 155: 323–326.
Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001). Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4: 399–408.
Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE (2004). The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment: but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 55: 1171–1178.
de Jong R, Groenink L, van der Gugten J, Olivier B (2002). The light-enhanced startle paradigm as a putative animal model of anxiety: effects of chlordiazepoxide, flesonoxan and fluvoxamine. Psychopharmacology 159: 176–180.
First MB, Spitzer RI, Williams JBW, Gibbon M (1995). Structured Clinical Interview for DSM-V (SCID). American Psychiatric Association: Washington, DC.
Funayama ES, Grillon C, Davis M, Phelps EA (2001). A double dissociation in the affective modulation of startle in humans effects of unilateral temporal lobectomy. J Cogn Neurosci 13: 721–729.
Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR et al (1987). An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7: 329–332.
Graeff FG, Viana MB, Mora PO (1997). Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 21: 791–799.
Griebel G, Moreau JL, Jenck F, Misslin R, Martin JR (1994). Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113: 463–470.
Grillon C, Ameli R (1998). Effects of threat of shock, shock electrode placement, and darkness on startle. Int J Psychophysiol 28: 223–231.
Grillon C, Ameli R, Woods SW, Merikangas K, Davis M (1991). Fear-potentiated startle in humans effects of anticipatory anxiety on the acoustic blink reflex. Psychophysiology 28: 588–595.
Grillon C, Baas JM (2003). A review of the modulation of startle by affective states and its application to psychiatry. Clin Neurophysiol 114: 1557–1579.
Grillon C, Baas JMP, Pine DS, Levine J, Lawley M, Ellis V (2005). The benzodiazepine alprazolam reduces contextual fear but not cued fear potentiated startle in humans. 60th Annual Meeting of the Society of Biological Psychiatry. Atlanta, GA.
Grillon C, Baas JMP, Pine DS, Lissek S, Lawley M, Ellis V et al (in press). The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biol Psychiatry (in press).
Grillon C, Baas JP, Lissek S, Smith K, Milstein J (2004). Anxious responses to predictable and unpredictable aversive events. Behav Neurosci 118: 916–924.
Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM (2002). Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology 163: 106–110.
Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM (2003a). Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28: 148–152.
Harmer CJ, Rogers RD, Tunbridge E, Cowen PJ, Goodwin GM (2003b). Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology 167: 411–417.
Hensman R, Gaimaraes FS, Wang M, Deakin JFW (1991). Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology 104: 220–224.
Inoue T, Li XB, Abekawa T, Kitaichi Y, Izumi T, Nakagawa S et al (2004). Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur J Pharmacol 497: 311–316.
Inoue T, Tsuchiya K, Koyama T (1996). Serotonergic activation reduces defensive freezing in the conditioned fear paradigm. Pharmacol Biochem Behav 53: 825–831.
Kemp AH, Gray MA, Silberstein RB, Armstrong SM, Nathan PJ (2004). Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. Neuroimage 22: 1084–1096.
Lino-de-Oliveira C, Sales AJ, Del Bel EA, Silveira MC, Guimaraes FS (2001). Effects of acute and chronic fluoxetine treatments on restraint stress-induced Fos expression. Brain Res Bull 55: 747–754.
Lissek S, Dvir S, Baas JMP, Mc Dowell DJ, Pine DS, Shaywitz E et al (2005a). Pathological anxiety is associated with sustained anxiety to an unpredictably stressful context but not with phasic fear reactions to an explicit threat-cue. 60th Annual Meeting of the Society of Biological Psychiatry. Atlanta, GA.
Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C et al (2005b). Classical fear conditioning in the anxiety disorders a meta-analysis. Behav Res Ther 43: 1391–1424.
Morris JS, Ohman A, Dolan RJ (1998). Conscious and unconscious emotional learning in the human amygdala. Nature 393: 467–470.
Noble S, Benfield P (1997). Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 8: 410–431.
Phelix CF, Liposits Z, Paull WK (1992). Serotonin-CRF interaction in the bed nucleus of the stria terminalis: a light microscopic double-label immunocytochemical analysis. Brain Res Bull 28: 943–948.
Phelps EA, O'Connor KJ, Gatenby JC, Anderson AK, Grillon C, Davis M et al (1998). Activation of the human amygdala by a cognitive representation of fear: an FMRI study. Soc Neurosci Abstr 24: 1524.
Piñeyro G, Blier P (1999). Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51: 533–591.
Pollock BG (2001). Citalopram: a comprehensive review. Expert Opin Pharmacother 2: 681–698.
Ramos TT, Gentil V, Gorenstein C (1993). Clomipramine and initial worsening in panic disorder: beyond the ‘jitterness syndrome’. J Psychopharmacol 7: 265–269.
Sanchez C, Meier E (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129: 197–205.
Schulkin J, Morgan MA, Rosen JB (2005). A neuroendocrine mechanism for sustaining fear. Trends Neurosci 28: 629–635.
Silva M, Hetem LA, Guimaraes FS, Graeff FG (2001). Opposite effects of nefazodone in two human models of anxiety. Psychopharmacology (Berlin) 156: 454–460.
Spielberger CD (1983). Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press: Palo Alto, CA.
Vertes RP, Fortin WJ, Crane AM (1999). Projections of the median raphe nucleus in the rat. J Comp Neurol 407: 555–582.
Walker DL, Toufexis DJ, Davis M (2003). Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 463: 199–216.
Acknowledgements
This research was supported by the Intramural Research Program of the National Institutes of Mental Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grillon, C., Levenson, J. & Pine, D. A Single Dose of the Selective Serotonin Reuptake Inhibitor Citalopram Exacerbates Anxiety in Humans: A Fear-Potentiated Startle Study. Neuropsychopharmacol 32, 225–231 (2007). https://doi.org/10.1038/sj.npp.1301204
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301204
Keywords
This article is cited by
-
Anxiety Sensitivity and Intolerance of Uncertainty: Transdiagnostic Risk Factors for Anxiety as Targets to Reduce Risk of Suicide
Current Psychiatry Reports (2023)
-
The effect of SSRIs on fear learning: a systematic review and meta-analysis
Psychopharmacology (2023)
-
Pharmacological modulation of conditioned fear in the fear-potentiated startle test: a systematic review and meta-analysis of animal studies
Psychopharmacology (2023)
-
The role of serotonin in modulating common waxbill behaviour
Behavioral Ecology and Sociobiology (2023)
-
Isobolographic analysis of the antidepressant interaction in two-drug combinations of citalopram, bupropion, and scopolamine in mice
Naunyn-Schmiedeberg's Archives of Pharmacology (2022)
